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Abstract
Background: Human onchocerciasis or river blindness, caused by the filarial nematode Onchocerca volvulus, is
currently controlled using the microfilaricidal drug, ivermectin. However, ivermectin does not kill adult O. volvulus,
and in areas with less than 65% ivermectin coverage of the population, there is no effect on transmission.
Therefore, there is still a need for a macrofilaricidal drug. Using the bovine filarial nematode O. ochengi (found
naturally in African cattle), the macrofilaricidal efficacy of the modified flubendazole, UMF-078, was investigated.
Methods: Groups of 3 cows were treated with one of the following regimens: (a) a single dose of UMF-078 at
150 mg/kg intramuscularly (im), (b) 50 mg/kg im, (c) 150 mg/kg intraabomasally (ia), (d) 50 mg/kg ia, or (e) not
treated (controls).
Results: After treatment at 150 mg/kg im, nodule diameter, worm motility and worm viability (as measured by
metabolic reduction of tetrazolium to formazan) declined significantly compared with pre-treatment values and
concurrent controls. There was abrogation of embryogenesis and death of all adult worms by 24 weeks post-
treatment (pt). Animals treated at 50 mg/kg im showed a decline in nodule diameter together with abrogated
reproduction, reduced motility, and lower metabolic activity in isolated worms, culminating in approximately 50%
worm mortality by 52 weeks pt. Worms removed from animals treated ia were not killed, but exhibited a
temporary embryotoxic effect which had waned by 12 weeks pt in the 50 mg/kg ia group and by 24 weeks pt in
the 150 mg/kg ia group. These differences could be explained by the different absorption rates and elimination
half-lives for each dose and route of administration.
Conclusion: Although we did not observe any signs of mammalian toxicity in this trial with a single dose, other
studies have raised concerns regarding neuro- and genotoxicity. Consequently, further evaluation of this
compound has been suspended. Nonetheless, these results validate the molecular target of the benzimidazoles as
a promising lead for rational design of macrofilaricidal drugs.
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Background
Human onchocerciasis or river blindness, caused by the
filarial nematode Onchocerca volvulus, is endemic in 34
countries in Africa, the Americas and the Yemen, infecting
approximately 37 million people with a further 90 mil-
lion people considered to be at risk of infection in Africa
[1]. Beginning in 1974, control of the vector (Simulium
damnosum sensu lato) was the principle approach used by
the highly successful Onchocerciasis Control Programme
(OCP) in 11 endemic countries of West Africa, although
ivermectin distribution played a key role from 1987 [2].
The OCP was phased-out in 2002 and has been super-
seded by the African Programme for Onchocerciasis Con-
trol (APOC), which applies community-directed
treatment with ivermectin as an almost exclusive control
method in a further 19 endemic African countries. Iver-
mectin is currently supplied free-of-charge by Merck & Co.
under their Mectizan® Donation Programme [3,4].
Ivermectin is an extremely effective microfilaricide, rap-
idly removing microfilariae (mf) from the skin of infected
patients and thus preventing the development of blind-
ness and relieving skin irritation [5-7]. However, despite
its cumulative sterilising effect on the female worm, iver-
mectin does not appear to exhibit significant macrofilari-
cidal activity [8-11]. Furthermore, in order to prevent
sustained transmission, annual treatment coverage must
exceed 65% of the population [12]. Following analyses of
the post-control situation in the OCP region, there is a
consensus that onchocerciasis cannot be eradicated in
Africa using currently available methods alone [13,14].
The development of a safe, effective macrofilaricide suita-
ble for mass treatment, preferably as a single oral dose,
was the goal of the World Health Organisation's (WHO)
MACROFIL programme, which also received support
from OCP and APOC. Such a drug would be able to break
the transmission cycle and thus reduce the number of
years of treatment necessary to permanently eliminate
onchocerciasis as a public health problem in Africa.
There is little published information on the anthelminthic
properties of the modified flubendazole, UMF-078, but it
is has been shown to have both micro- and macrofilari-
cidal activity against Acanthocheilonema viteae and Litomo-
soides sigmodontis in jirds [15]. However, flubendazole
itself has been studied quite extensively. It has been
shown to be both micro- and macrofilaricidal depending
on the formulation and the route of administration [16-
18]. Using Onchocerca ochengi, a natural parasite of cattle
that is endemic in the Adamawa province of Cameroon
[19], the efficacy of UMF-078 was assessed in vivo by the
intramuscular or intraabomasal routes at two dosage
rates. This species is the closest existent relative of O. vol-
vulus  [20,21] and forms palpable, intradermal nodules
which can be removed under local anaesthetic. Conse-
quently, it was adopted as a tertiary drug screen for mac-
rofilaricides by WHO [22-24].
Materials and methods
Animals
Fifteen 4–6 year old Gudali cows (Bos indicus), each with
more than 20 palpable O. ochengi nodules in the ventral
abdominal skin, were purchased from local markets in the
Adamawa Province of Cameroon. They were kept on pas-
ture at the Institut de Recherche Agricole pour le Dévelop-
pement (IRAD), formerly the Institut de Recherche
Zootechniques et Vétérinaires (IRZV), Wakwa, 10 km SW
of Ngaoundéré. This location is at an altitude of 1000 m
where the annual transmission potential (ATP) for O.
ochengi is low [approximately 600 infective larvae per ani-
mal per year (Renz and Bronsvoort, unpublished observa-
tions)].
Twenty O. ochengi nodules per animal were identified,
their locations noted, and their periphery marked by tat-
too ink. Subsequently, a microchip transponder (Identi-
chip®, Animalcare Ltd., York, UK) was subcutaneously
implanted adjacent to each nodule. Each transponder car-
ried a unique 10-digit number that was visualised using a
hand-held reader. In previous experiments, these micro-
chips remained in position for at least 2 years and enabled
individual nodules to be identified consistently.
Chemotherapy
UMF-078, methyl(+/-)5-[α-amino-4 fluorobenzyl]benz-
imidazole-2-carbamate, was provided as a white desic-
cated powder. This was suspended in peanut oil (Sigma
UK) at a final concentration of 180 mg/ml.
The cattle had a mean weight of 316 kg (SD = 32 kg) and
were ranked according to nodule load per animal (mean
= 63 nodules; SD = 39 nodules). The four treatment and
one control groups were randomly numbered 1–5 and the
highest ranking animal randomly assigned to a group. The
remaining cattle (in rank order) were then assigned in
turn to each treatment group (in order of their number) to
give a similar mean number and range of nodules in each
group of three animals.
Intramuscular (im) injections (150 mg/kg or 50 mg/kg)
were delivered in the gluteal and/or triceps muscles with a
maximum of 50 ml of the suspension per site. Intraabo-
masal (ia) injections (150 mg/kg or 50 mg/kg) were
administered into the lumen of the pyloric region of the
abomasum following a right-sided laparotomy and exteri-
orisation of the pylorus [25]. The wounds were closed
using monofilament nylon mattress sutures and the ani-
mals were treated for a week with Duplocillin LA®
(Intervet, UK). All animals recovered without incident.Parasites & Vectors 2008, 1:18 http://www.parasitesandvectors.com/content/1/1/18
Page 3 of 10
(page number not for citation purposes)
Observations
Microfilarial densities were determined as previously
described (Renz et al., 1995; Tchakouté et al., 1999). In
brief, superficial skin biopsies were obtained from the
ventral mid-line (on the same morning for all groups) and
incubated for 24 h in 0.5 ml antibiotic-supplemented
Roswell Park Memorial Institute medium (RPMI 1640,
Sigma UK). The biopsies were then digested in 0.5% col-
lagenase for 24 hours. Viable mf that had emerged into
the medium, together with residual mf present in digested
skin, were counted by microscopy and total densities
expressed per 100 mg of skin. The geometric mean
number of mf per 100 mg of skin from the three biopsies
for each animal was calculated using the log+1 transfor-
mation. The mean per group was calculated in a similar
way.
Four nodules were removed per animal under local anaes-
thetic at each time-point. If a nodule had apparently
resolved, its position was localised by microchip and the
incision was guided by the peripheral tattoo.
All each time-point, nodules were examined by a techni-
cian blinded to the treatment group by the triple assay
described by Renz et al. [24] with some modification.
After trimming the nodule, the capsule was incised and
the adult worm squeezed out into 200 μl PBS on a depres-
sion slide and males picked out. The first 5 mm of the
anterior end of the females was incised. Male and female
worms were incubated in 200 μl of RPMI in microtitre
plate. After incubation (30 minutes, 37°C), the motility
of the male worms and female anterior ends (mean length
± SD = 8.3 ± 2.6 mm) was scored on a 3 point scale (0 =
no movement after 30 seconds of observation; 1 = weak,
slow or intermittent movement; 2 = vigorous movement).
Individual worm viability was assessed by the metabolic
reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-di-phe-
nyltetrazolium bromide (MTT) to formazan [24,26].
Worms were incubated for 1 hour in MTT and then the
colour was leached out of the worms by 1/2 hour incuba-
tion in DMSO. The optical density of the formazan reduc-
tion product was determined on a photospectrometer
(Cambridge Life Instruments) at 492 nm and standard-
ised per 10 mm of worm.
The remaining portion of the female worm was trans-
ferred into a mortar with PBS (final volume, 2 ml), gently
crushed with a pestle, and a sample transferred to a Fuchs-
Rosenthal chamber (3.2 μl). A count (embryogram) was
then performed by microscopy, differentiating between
each intrauterine developmental stage and between nor-
mal and pathological embryos [27].
Drugs and pharmacokinetics
UMF-078, UMF-060 and flubendazole were obtained
from the MACROFIL Programme, WHO. Ammonium
acetate, high-pressure liquid chromatography (HPLC)-
grade methanol, diethyl ether, dimethyl sulphoxide
(DMSO) and acetic acid were obtained from Fisher Scien-
tific (Fair Lawn, NJ, USA). A C18 reversed-phase stainless
steel column (150 × 4.6 minimum internal diameter; 5
μm particle size; Inertsil ODS-2) was supplied by Alltech
(Deerfield, IL, USA).
Plasma UMF-078 and its two metabolites, UMF-060 and
flubendazole, were determined by HPLC as described by
Ramanathan et al. [28]. The detection limits of UMF-078,
UMF-060 and flubendazole in plasma were 7, 5 and 7 ng/
ml, respectively. The absolute recoveries of the extraction
procedure were determined by comparing the peak areas
obtained from extracted plasma samples with those
obtained from equivalent amounts of the 3 compounds
(UMF-078, UMF-060 and flubendazole) in DMSO by
direct injection. For UMF-078, the mean recoveries of var-
ious concentrations ranged from 80.5 to 84.0%; for UMF-
060, 88.1 to 89.6%; and for flubendazole, 97.1 to 98.6%.
Intraday precision was performed by repeating the analy-
sis of four concentration sets for UMF-078, UMF-060 and
flubendazole. The coefficients of variation were <6% for
all compounds and all measured concentrations were
within the range ± 20% of the actual value.
Statistical Analyses
Data were analysed using the Stata® version 9 statistical
package (Stata Corp., Texas, USA). The generalised linear
latent and mixed models (gllamm) package was used for
multi-level models [29]. Continuous response variables
(mff, nodule size and MTT) were modelled with a normal
error structure. The fixed effects of treatment group and
time and their interaction were modelled for each
response with a random intercept to allow for the repeat
samples from the same animal. A reduced model for each
response was analysed for a single time point at 24 weeks
and the effect of each treatment group estimated in com-
parison to the control group. Assumptions of normality
were checked using the qnorm plot and tested using the
Wilks-Shapiro test of normality. Where the linear assump-
tions were not met the non parametric Kruskal-Wallis
ANOVA was used which is based on ranks, however, this
analysis can not include the multi-level structure of the
data.
A non-compartmental analysis in WinNonlin software
(Scientific Consulting, Inc., Apex, NC, USA) was used to
characterize UMF-078 plasma concentration-time pro-
files. The terminal half-life (t1/2) was estimated using the
last 3 or 4 data points from each curve using nonlinear
regression. The area under the plasma concentration-timeParasites & Vectors 2008, 1:18 http://www.parasitesandvectors.com/content/1/1/18
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curve (AUC) was calculated by the linear trapezoidal rule
from T = 0 to the last measured concentration (tlast).
Results
Microfilariae
The geometric mean mf densities per 100 mg of skin are
presented in Table 1 where the large amount of variation
between animals even before trestment can be clearly
seen. In the two groups treated im, there was a decline in
mf density over the 72 weeks that this was monitored.
This was more rapid in the higher dose im group. For the
higher ia dose of 150 mg/kg, there was an initial sharp
decline in mf density; however, mf density then
rebounded by 24 weeks pt to approximately 100 mf per
100 mg skin (similar to the untreated controls), and this
was maintained through to 72 weeks pt (final observa-
tion). The statistical analysis based on the log+1 of the raw
mff counts (Table 2) shows a highly significant effect of
both treatment group and time as well as an interaction
between them. Only the interactions between time and
the im treatment groups were highly significant (p <
0.001). At 24 weeks post treatment the results suggest that
UMF-078 given at the higher drop by the im route pro-
duces a significant decline in mff compared to the con-
trols. This appears to be a permanent decline in mf density
as there is no evidence of recovery by 72 weeks.
Nodule diameter, males per nodule, female motility scores 
and female viability (OD492/10 mm)
The nodule diameter and triple assay scores are presented
in Table 3. In the 150 mg/kg im-treated group, there was
a rapid decline in nodule size which was already apparent
by 3 weeks pt on palpation of the nodules in vivo. At 24
weeks pt, many nodules could only be located using the
microchip scanner and they were statistically significantly
smaller for the higher-dose im group compared to the
controls (Table 2). After biopsy, a small calcified mass
could be found in the fascia, but by 52 weeks pt no nod-
ules could be found. From a total of 186 nodules at the
start of the study none could be palpated at 52 weeks pt,
demonstrating an unequivocal shrinkage and disappear-
ance of nodules in this high-dose treatment group. In the
50 mg/kg im group, nodule size started to decline by 24
weeks pt but this was not significant (p = 0.679). At 52
weeks pt, no nodules could be palpated in one animal,
but were still palpable and within the normal range in the
remaining 2/3 animals. There were statistically significant
treatment group, time and treatment group time interac-
tions effects (Table 2) and this was due to both im groups
having significant time interactions. Comparisons with
the controls at 24 weeks showed no statistically significant
difference in nodule diameter of the low dose im group or
either of the groups treated by the ia route compared to
the controls.
The numbers of males found in each nodule fluctuated
considerably between time ponts even within the control
group. By 24 weeks pt there were no male worms recov-
ered from nodules treated at 150 mg/kg im and similarly
at 52 weeks pt for the 50 mg/kg im group. In the other
groups, males were recovered in normal numbers
throughout the experiment. The counts of males count
not be fit to a linear modelin gllamm and a non paramet-
ric Kruskal Wallis ANOVA was used on the ranks and did
not include an adjustment for the repeated multi-level
data structure. However, based on an ANOVA there was a
strongly significant difference between the number of
males in the control and high dose im treatment group.
Table 1: Geometric mean (3 skin snips) O. ochengi mf density+1 per 100 mg skin in cattle following a single treatment of UMF-078 at 
150 mg/kg or 50 mg/kg and by the intramuscular or intraabomasal routes of administration. 
treatment group ID 0 wpt 1 wpt 4 wpt 12 wpt 24 wpt 42 wpt 52 wpt 72 wpt
Control 42 125.7 83.7 61.7 104.3 88.9 24.1 5.2 124.9
46 5.1 135.8 256.5 60.3 72.7 7.8 16.2 139.3
61 30.7 151.4 49.3 122.2 14.6 1237.0 32.9 47.0
150 mg/kg UMF-078 im 74 2298.1 238.8 0.0 0.0 0.0 0.0 - 0.8
88 1237.6 959.4 0.0 0.0 4.3 0.0 - 0.0
92 3069.9 713.4 111.1 10.0 14.4 1.6 - 0.0
50 mg/kg UMF-078 im 79 392.7 415.9 329.4 4.6 15.3 0.0 1.3 0.0
80 556.8 57.6 25.6 26.1 13.4 30.6 24.0 0.0
90 1998.6 934.5 164.7 357.6 73.0 10.0 6.2 20.8
150 mg/kg UMF-078 ia 81 76.2 138.6 5.6 18.2 142.6 77.7 - 11.5
85 309.9 17.8 1.2 0.0 118.5 139.4 - 359.1
91 989.5 41.4 18.9 0.0 0.0 * * *
50 mg/kg UMF-078 ia 82 1010.3 46.1 26.3 93.0 2.8 67.1 - 83.9
84 3141.6 541.5 477.7 589.3 217.1 116.8 - 317.6
93 1163.2 165.5 99.6 5.7 140.7 305.4 - 91.5
Animals lost to follow-up are indicated in the table by (*) and sample not collected by (-).Parasites & Vectors 2008, 1:18 http://www.parasitesandvectors.com/content/1/1/18
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The motility of female anterior ends in the 150 mg/kg im
group started to decline immediately and by 12 weeks pt
their motility was zero. The group treated at 50 mg/kg im
showed a decline to 0.8 by 12 weeks, but recovered to a
score of 2 by 24 weeks only to decline to zero at 52 weeks
pt. However, these median data do not reflect the
observed disappearance of worms from one animal in this
group. A non-parametric Kruskal-Wallis ANOVA was used
as the residuals from the gllamm procedure were not nor-
mal violating the assumptions of the model. This non-
parametric approach did not allow the multi-level struc-
ture of the data to be included in the estimation process.
There was a significant difference in female motility scores
for the high dose im treatment group but no statistically
significant difference between the other three groups and
the controls (Table 2).
The viability (OD492) of females appeared to have
declined in all the groups including the controls by 24
weeks pt. In the 150 mg/kg im treatment group, viability
scores declined markedly after treatment and worms were
no longer viable (OD492 < 0.1) by 12 weeks pt. In the 50
mg/kg im group there was a marked decline in viability by
12 weeks pt, but by 52 weeks mean viability had returned
to pre-treatment levels (OD492 = 0.17) in worms obtained
from intact nodules. However, in addition to the resolu-
Table 2: Results of multilevel model for each of the variables measured. 
Mff+ Nodule diameter+ /nodule# MOT# OD492
+
Interaction (time*trtgrp) <0.001 <0.001 ND ND 0.054
Fixed effect (time) <0.001 <0.001 ND ND 0.001
Individual treatments compared to controls at 24 weeks
150 mg/kg UMF 078 im 0.005 0.002 0.001 <0.001 <0.001
50 mg/kg UMF 078 im 0.481 0.679 0.006 0.103 0.008
150 mg/kg UMF 078 ia 0.729 0.789 0.927 0.952 0.179
50 mg/kg UMF 078 ia 0.155 0.347 0.189 0.482 0.858
These were run using the gllamm procedure in STATA9 with either a linear(+) error structure and a random intercept, non parametric Kruskal 
Wallis ANOVA (#).
Table 3: Mean nodule diameters (mm), mean number of males per nodule (/nodule), median female motility score ( MOT) and 
mean female viability (as OD492 values per 10 mm length; see text) ( OD492) for O. ochengi recovered from cattle before and up to 52 
weeks after a single dose of UMF-078 at 2 doses (50 and 150 mg/kg) and by 2 routes of administration (im = intramuscularly; ia = intra 
abomasally). 
Weeks 031 2 2 4 5 2
control nodule diameter 8.7 8.0 7.5 6.3 7.1
/nodule 0.7 1.7 1.5 1.3 0.5
MOT 2.0 2.0 2.0 2.0 1.5
OD492 0.22 0.21 0.32 0.15 0.10
150 mg/kg UMF 078 im nodule diameter 8.5 6.5 6.0 3.3 ND
/nodule 0.2 0.7 0.1 0.0
MOT 2.0 1.5 0.0 0.0
 OD492 0.29 0.12 0.01 0.0
50 mg/kg UMF 078 im nodule diameter 7.7 7.7 6.3 5.9 5.6
/nodule 1.0 0.5 0.3 0.3 0.0
MOT 2.0 2.0 0.8 2.0 0
OD492 0.31 0.13 0.06 0.11 0.17
150 mg/kg UMF 078 ia nodule diameter 7.7 7.8 7.2 6.6 ND
/nodule 1.5 0.5 0.5 1.0
MOT 2.0 2.0 2.0 2.0
 OD492 0.31 0.13 0.16 0.18
50 mg/kg UMF 078 ia nodule diameter 7.5 8.5 7.3 7.2 ND
/nodule 0.5 0.3 0.8 0.6
MOT 2.0 2.0 2.0 2.0
 OD492 0.14 0.15 0.14 0.14
N.B. The numbers of  per nodule are not given, as 231 of the 240 nodules examined contained a single female. In addition, the male motility and 
MTT reduction/formazan formation data are not presented here because of the small numbers of males recovered after treatment.
ND = not done.Parasites & Vectors 2008, 1:18 http://www.parasitesandvectors.com/content/1/1/18
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tion of all nodules from one animal from this group, 2 of
4 nodules from a second animal treated 50 mg/kg im did
not contain viable worms. At 24 weeks pt, the two im
treatment groups had statistically lower viability scores
compared to the controls. There was no statistically signif-
icant effect on viability of worms recovered from animals
treated ia compared to controls at 24 weeks pt.
Embryogenesis
Embryograms are presented in Figure 1. There were both
quantitative and qualitative changes in the embryograms
in both im treated groups, with a greater and more rapid
effect in the higher dose group. These changes were slower
in onset in the fully developed intrauterine mf. In groups
treated ia, there was an increase in pathological forms and
decrease in total intrauterine contents at 3 weeks pt,
although at later times pt, embryograms and thus repro-
duction returned to normal. There was a increase in the
percentage of pathological embryonic stages by 12 weeks
pt in both im treatment groups compared to the controls,
and for intrauterine mf in the high-dose im group only
compared to the controls. Comparisons between percent-
ages of pathological stages at 24 weeks pt were not possi-
ble, as over half the nodules had no embryonic or
intrauterine mf present.
Pharmacokinetics
UMF-078 absorption after im dosing was prolonged (Fig-
ure 2A), with mean Tmax of 225 and 312 hours for the 50
and 150 mg/kg dosages, respectively. The mean Cmax was
39 and 91 ng/ml for the 50 and 150 mg/kg dosages,
respectively. The elimination half-life was estimated at
425 for the 50 mg/kg dose and 419 hours for the 150 mg/
kg dose. The extent of absorption was highly variable, but
there was a roughly proportional increase in the AUC with
dose for the 50 and 150 mg/kg dosages (11,304 vs. 35,386
ng/ml × h).
UMF-078 absorption following ia dosing was variable
(Figure 2B), with mean Cmax of 1638 and 3895 ng/ml for
the 50 and 150 mg/kg dosages, respectively, and mean
Tmax reached at about 4.7 and 24 hours, respectively. The
elimination half-life was estimated at 16.9 and 38 hours
for the 50 and 150 mg/kg dosages, respectively. The extent
of absorption (AUC) after ia administration was highly
variable, with a 6-fold increase in the AUC0-168 h when
the 50 and 150 mg/kg dosages were compared (40,986 vs.
271,250 ng/ml × h).
Discussion
The benzimidazoles are a large group of compounds used
extensively in both human and veterinary medicine for
the treatment of nematode infestations. UMF-078 is a
modified form of flubendazole designed for parenteral
injection; following which it is quickly metabolised to
UMF-060 and the active parent molecule. In contrast, the
standard preparation of flubendazole is insoluble and
poorly absorbed across the intestinal mucosa [30]. As an
aqueous suspension, it was not macrofilaricidal against
Brugia pahangi per os [17], but when micronised the oral
preparation was both macro- and microfilaricidal [18]. It
has also been used successfully against Breinlia booliati in
rats by repeated subcutaneous injection [16], although
this route of administration caused abcessation and local
inflammation. No such reactions were observed in the
current study with UMF-078.
In this experiment, we have shown that UMF-078 (when
delivered systemically) is a potent macrofilaricide against
the naturally-occurring, skin-dwelling parasite, O. ochengi
when given at 150 mg/kg im. The specific target for the
drug was not investigated in this experiment, but it could
act by at least two distinct (but not mutually exclusive)
mechanisms. Firstly, it may cause lethal damage to the
intestine by binding to the cytoplasmic microtubules of
absorptive cells [31], leading to starvation and ultimately
death by interference with glucose uptake. Secondly, it
could induce neurotoxic effects via a predilection for neu-
rotubules (and possibly neurofilaments), as postulated
for febantel and mebendazole against the nematode Het-
erakis spumosa [32], and benomyl against the annelid Eise-
nia foetida [33]. Indeed, neurological side-effects in the
mammalian host were observed after repeated dosing
with UMF-078 (see below), suggesting that it may exhibit
greater activity against the nervous system than other ben-
zimidazoles. Drug effects were both dose and route
dependent (with individual variation in peak levels in
plasma reflected in the variation in efficacy against nod-
ules within each group), demonstrating a requirement for
sustained plasma drug concentrations, as previously
reported by Court [34] and Devaney et al. [35].
Albendazole is currently used in combination with
diethylcarbamazine or ivermectin for mass drug adminis-
tration by the Global Programme to Eliminate Lymphatic
Filariasis [36]. The additive or synergistic effect of this
benzimidazole, if any, when used in combination with
other anthelminthics for the treatment of lymphatic
filariasis remains controversial, particularly with regard to
macrofilaricidal efficacy [37-40]. Certainly, albendazole
had no significant micro- or macrofilaricidal activity in
clinical trials for human onchocerciasis conducted in the
early 1990s, although it induced embryotoxic effects in
female worms [41,42]. Whether the more demonstrable
macrofilaricidal efficacy of UMF-078 is an intrinsic char-
acteristic of the drug (e.g. due to a predilection for the
nematode nervous system as discussed above) or related
to enhanced systemic availability will require evaluation
of albendazole against O. ochengi, which has not been per-
formed to date.Parasites & Vectors 2008, 1:18 http://www.parasitesandvectors.com/content/1/1/18
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Mean total numbers (×1000) of embryonic stages and intra-uterine mf (iu-mf) '' overlaid with the number of abnormal/path- ological stages '■' (n = 12, except at 0 weeks where n = 6) Figure 1
Mean total numbers (×1000) of embryonic stages and intra-uterine mf (iu-mf) '' overlaid with the number of 
abnormal/pathological stages '■' (n = 12, except at 0 weeks where n = 6). Data represent the median percent of 
pathological forms for embryograms of female O. ochengi recovered from cattle before and up to 52 weeks after a single dose 
of UMF-078 at 2 dose rates (50 and 150 mg/kg) and administered by 2 routes (im = intramuscularly; ia = intraabomasally).
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A. Plasma concentration-time profiles for UMF-078 after intramuscular administration of 50 mg/kg, and 150 mg/kg Figure 2
A. Plasma concentration-time profiles for UMF-078 after intramuscular administration of 50 mg/kg, and 150 
mg/kg. B. Plasma concentration-time profiles for UMF-078 after intraabomasal administration of 50 mg/kg and 150 mg/kg). 
Data are means ± S.D. (n = 3).
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The effects of UMF-078 on embryogenesis were apparent
at both doses and by both routes. However, by the ia route
(which was used to mimic oral administration in
monograstric species such as man) the effects were tran-
sient and although embryonic and intrauterine mf were
fatally damaged, there was no lasting effect on oogenesis
and no accumulation of dead and dying stages in the
uterus. Thus, UMF-078 disrupts embryonic development
but in contrast with the avermectins [43], uterine activity
is not disturbed and dead and dying mf are eliminated
from the uterus and from within the nodule allowing
insemination and a new reproductive cycle [44]. In our
experiment, normal numbers and morphological integ-
rity had returned by 12 and 24 weeks for the embryonic
and intrauterine mf, respectively, following a single ia
treatment.
In this experiment, single ia or im administration of UMF-
078 did not produce any apparent acute or chronic toxic
signs. However, repeated oral dosing of an aqueous sus-
pension in dogs (WHO internal report) led to lethal neu-
rotoxic side effects. We also observed severe neurotoxicity
in cattle after two doses of UMF-078 at 150 mg/kg per os
(Trees et al., 1998; and A.J. Trees, unpublished observa-
tions), and this trial had to be abandoned for welfare rea-
sons. Data indicating that certain benzimidazoles can also
induce genotoxicity ([45] and WHO internal report) and
cytotoxicity [46] are of related concern, and as a result fur-
ther development of UMF-078 as a macrofilaricide has
been halted.
The current distribution of ivermectin has been very suc-
cessful in reducing the morbidity due to O. volvulus [47];
however, interruption of transmission in Africa by iver-
mectin alone is not achievable [13,14]. This emphasises
the need to upgrade the search for a practicable macrofila-
ricidal regimen for chemotherapy of O. volvulus. The best
tolerated candidate drugs presently available are anti-rick-
ettsial compounds that target endosymbiotic bacteria
(Wolbachia) within filarial tissues [48], but these therapies
have to be prolonged to achieve macrofilaricidal effects
[49] and so are unsuitable for mass administration [50].
The results presented here strongly validate the potential
of β-tubulin, the binding site of benzimidazoles [51], as a
key molecular target for rational drug design of macrofila-
ricides. However, they also draw attention to potential
effects on the nervous system that could extend beyond
the parasite to the host., Nevertheless, benzimidazoles
with an excellent safety profile (such as albendazole)
should be evaluated in combination with antibiotics to
determine if synergistic effects against adult worms can be
achieved.
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